Mandate

Vinge advises Bridgepoint in conjunction with its investment in Vitamin Well

November 29, 2016

Vinge has advised Bridgepoint Development Capital in conjunction with its investment in Vitamin Well AB. Vitamin Well AB is a leading Nordic company within functional drinks, which develops, markets and sells high-quality drinks under the well-known trademarks Vitamin Well, Vitamin Well Free, NOBE aloe vera, NOCCO and the sports drink Vitamin Well+.

Following its formation in 2006, Vitamin Well AB has had the vision of being the best and the tastiest functional drinks manufacturer, adapted for various different target groups and situations. Vitamin Well has its headquarters in Stockholm, employs 84 persons and its drinks are sold in 28 countries. The transaction is conditional upon approval from the Swedish Competition Authority.

Vinge’s team consists of partner Daniel Rosvall together with, among others, associates Samra Baytar and Ilze Lukins (M&A), Tomas Forsgren (intellectual property), Lisa Sennerby (employment), Kristoffer Larson (real estate), Albert Wållgren and Karl Klackenberg (banking & finance) and counsel Johan Cederblad (regulatory issues). Grant McKelvey and Marita Ljunggren are advising on competition law notification issues.

 

Related

Vinge advises Isofol Medical AB (publ) in connection with its rights issue of units

Through the rights issue of units, consisting of shares and warrants, and the exercised over-allotment issue, Isofol will receive approximately SEK 84 million and may receive an additional maximum of approximately SEK 110 million upon exercise of all warrants at the highest subscription price.
August 01, 2025

Vinge advises Oncorena in connection with share issue

Vinge advises Oncorena Holding AB in connection with a share issue of approximately SEK 133 million.
July 30, 2025

Vinge advises Karl Hedin and minority owners on the sale of AB Karl Hedin Sågverk to Vida

Vinge has advised Karl Hedin and minority shareholders in connection with the sale of AB Karl Hedin Sågverk to Vida Aktiebolag (“Vida”).
July 24, 2025